Misplaced Pages

Rubitecan: Difference between revisions

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 15:48, 30 July 2010 editPotatoBot (talk | contribs)Bots51,239 editsm Stub sorting and placement of stub template(s): antineoplastic-drug-stub← Previous edit Revision as of 19:15, 20 April 2011 edit undoCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation (Next edit →
Line 1: Line 1:
{{Drugbox {{Drugbox
| verifiedrevid = 376278337
| IUPAC_name = (4''S'')-4-ethyl-4-hydroxy-11-nitro-1''H''-pyranoindolizinoquinoline-3,14(4''H'',12''H'')-dione | IUPAC_name = (4''S'')-4-ethyl-4-hydroxy-11-nitro-1''H''-pyranoindolizinoquinoline-3,14(4''H'',12''H'')-dione
|synonyms = <small>(19''S'')-19-ethyl-19-hydroxy-10-nitro-17-oxa-3,13-diazapentacyclohenicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione</small> |synonyms = <small>(19''S'')-19-ethyl-19-hydroxy-10-nitro-17-oxa-3,13-diazapentacyclohenicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione</small>

Revision as of 19:15, 20 April 2011

Pharmaceutical compound
Rubitecan
File:Rubitecan.png
Clinical data
Other names(19S)-19-ethyl-19-hydroxy-10-nitro-17-oxa-3,13-diazapentacyclohenicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
Routes of
administration
Oral
ATC code
  • none
Identifiers
IUPAC name
  • (4S)-4-ethyl-4-hydroxy-11-nitro-1H-pyranoindolizinoquinoline-3,14(4H,12H)-dione
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H15N3O6
Molar mass393.349 g/mol g·mol
  (verify)

Rubitecan (INN, marketing name Orathecin) is an oral topoisomerase inhibitor, developed by Supergen.

History

On January 27, 2004, Supergen announced that it has completed the submission of an NDA for rubitecan to the US FDA, and was accepted for filing on March 2004.

On January 2005, Supergen withdrew the NDA for rubitecan, based on feedback indicating that the current data package would not be sufficient to gain US approval, and on January 2006, the Marketing Authorization Application (MAA) filed with the European Medicines Agency (EMA) was also withdrawn.

References

  1. "Drugs.com, SuperGen completes submission of New Drug Application (NDA) for Orathecin as an oral treatment for pancreatic cancer". Retrieved 2008-03-25.
  2. "Drugs.com, SuperGen's New Drug Application for Orathecin (rubitecan) capsules accepted by FDA for filing". Retrieved 2008-03-25.
  3. "Drugs.com, SuperGen Announces Withdrawal of Orathecin NDA". Retrieved 2008-03-25.
  4. "Press release from the EMEA website regarding withdrawal of Orathecin MAA" (PDF). Retrieved 2008-03-25.
Intracellular chemotherapeutic agents / antineoplastic agents (L01)
SPs/MIs
(M phase)
Block microtubule assembly
Block microtubule disassembly
DNA replication
inhibitor
DNA precursors/
antimetabolites
(S phase)
Folic acid
Purine
Pyrimidine
Deoxyribonucleotide
Topoisomerase inhibitors
(S phase)
I
II
II+Intercalation
Crosslinking of DNA
(CCNS)
Alkylating
Platinum-based
Nonclassical
Intercalation
Photosensitizers/PDT
Other
Enzyme inhibitors
Receptor antagonists
Other/ungrouped


This article is a stub. You can help Misplaced Pages by expanding it.

Categories:
Rubitecan: Difference between revisions Add topic